Ipsen (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average of $29.17

Shares of Ipsen S.A. (OTCMKTS:IPSEYGet Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $29.17 and traded as high as $33.20. Ipsen shares last traded at $33.20, with a volume of 345 shares traded.

Ipsen Price Performance

The stock’s 50-day simple moving average is $30.21 and its 200-day simple moving average is $29.17.

Ipsen Company Profile

(Get Free Report)

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

Further Reading

Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.